Effect of Low-Dose Aspirin on Vascular Inflammation, Plaque Stability, and Atherogenesis in Low-Density Lipoprotein Receptor–Deficient Mice
暂无分享,去创建一个
D. Praticò | Lei Zhao | C. Funk | T. Cyrus | Syuan Sung | Syun Tang
[1] G. FitzGerald,et al. Lipid Peroxidation and Platelet Activation in Murine Atherosclerosis , 2001, Circulation.
[2] P. Mills,et al. The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. , 2001, Journal of the American College of Cardiology.
[3] W. Kisiel,et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. , 2001, The Journal of clinical investigation.
[4] J. Schroeder,et al. Selective inhibition of interleukin-4 gene expression in human T cells by aspirin. , 2001, Blood.
[5] G. FitzGerald,et al. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[6] D. Rader,et al. Reduction of Isoprostanes and Regression of Advanced Atherosclerosis by Apolipoprotein E* , 2001, The Journal of Biological Chemistry.
[7] S. Han,et al. Effect of acetylsalicylic acid on endogenous IκB kinase activity in lung epithelial cells , 2001 .
[8] J. Joven,et al. The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice. , 2000, Life sciences.
[9] G. FitzGerald,et al. Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. , 2000, Blood.
[10] A. Siegbahn,et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. , 2000, The New England journal of medicine.
[11] R. Cohen,et al. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[12] C Warlow,et al. Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. , 2000, Stroke.
[13] M. Matsuhisa,et al. Antiplatelet drugs attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. , 2000, Thrombosis research.
[14] P. Groot,et al. Chemokines and atherosclerosis. , 1999, Atherosclerosis.
[15] K. Williams,et al. Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.
[16] P. Libby,et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. , 1999, Circulation.
[17] S. L. Murphy,et al. Deaths: final data for 1996. , 1998, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[18] P. Libby,et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. , 1998, Molecular cell.
[19] P. Libby,et al. Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization. , 1998, The American journal of medicine.
[20] C. Serhan. Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity? , 1997, Prostaglandins.
[21] R. Knuechel,et al. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. , 1996, The Journal of clinical investigation.
[22] S. Ghosh,et al. Inhibition of NF-kappa B by sodium salicylate and aspirin. , 1994, Science.
[23] T. Collins. Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. , 1993, Laboratory investigation; a journal of technical methods and pathology.
[24] H. Hecker,et al. Dose‐Dependent Effect of Aspirin on Carotid Atherosclerosis , 1993, Circulation.
[25] G. FitzGerald,et al. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. , 1991, The New England journal of medicine.
[26] L. Bolognese,et al. RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.
[27] E. Veys,et al. HL-A AND INFECTIVE SACROILEITIS , 1974 .